Table 2.
Biomarkers: comparison of controls and PD patients
| Parkinson’s Disease | Controls | ||||
| N = 154 | N = 99 | ||||
| Median [IQR] | Missing | Median [IQR] | Missing | p | |
| Telomere length (TL) Baseline (T/S ratio) | 0.78 [0.63,0.91] | 20.78% | 1.03 [0.81,1.31] | 22.22% | p < 0.001a |
| TL change/month† | –0.020 [–0.028,–0.013] | 20.78% | –0.012 [–0.023,–0.006] | 22.22% | p = 0.002a |
| p21 Baseline (A.U.) | 1.16 [0.83,1.73] | 6.49% | 1.62 [1.01,2.43] | 6.06% | p < 0.001a |
| p21 change/month | 0.002 [–0.028,0.046] | 20.78% | –0.006 [–0.044,0.036] | 23.23% | |
| p16 Baseline (A.U.) | 1.24 [0.77,1.92] | 6.49% | 1.41 [0.94,1.97] | 5.05% | |
| p16 change/month | 0.005 [–0.031,0.045] | 20.78% | –0.001 [–0.032,0.043] | 23.23% | |
| CRP (ng/ml) | 1.63 [0.66,3.48] | 12.34% | 1.83 [0.73,3.59] | 6.06% | |
| TNF alpha (pg/ml) | 2.98 [2.45,3.62] | 12.34% | 1.67 [1.39,2.11] | 6.06% | p < 0.001a |
| IL-6 (pg/ml) | 0.64 [0.43,0.99] | 13.64% | 0.60 [0.42,0.81] | 6.06% | |
| IL-10 (pg/ml) | 0.24 [0.17,0.35] | 16.23% | 0.19 [0.13,0.27] | 12.12% | p = 0.002a |
| IFNg (pg/ml) | 5.92 [4.11,8.80] | 12.34% | 5.80 [4.32,9.03] | 6.06% | |
| Inflammatory score | 0.01 [–0.84,1.26] | 17.53% | –1.26 [–1.85,–0.17] | 12.12% | p < 0.001a |
aIndependent-Samples Mann-Whitney U test significant after Benjamini-Hochberg multiple test correction. †For this composite variable, larger value = lower telomere shortening rate, see text.